Immune checkpoint inhibitor-related myocarditis

Jpn J Clin Oncol. 2018 Jan 1;48(1):7-12. doi: 10.1093/jjco/hyx154.

Abstract

Immune checkpoint inhibitors have demonstrated significant clinical benefit in many cancers. The clinical benefit afforded by these treatments can be accompanied by a unique and distinct spectrum of adverse events. Recently, several fatal cases of immune checkpoint inhibitor-related myocarditis were reported. Although its frequency is comparatively lower than that of other immune-related adverse events, myocarditis can lead to circulatory collapse and lethal ventricular arrhythmia. Immune checkpoints, cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1), play important roles in establishing peripheral tolerance to the heart. Evidence from studies using genetically engineered mouse models suggests that CTLA-4 signaling terminates proliferation and promotes anergy during the primary response to cardiac self-peptide recognition. PD-1 signaling restrains autoreactive T cells that enter the peripheral tissues and recognize cardiac-peptide, maintaining them in an anergic state. Patients affected by immune checkpoint inhibitor-related myocarditis often experience rapid onset of profound hemodynamic compromise progressing to cardiogenic shock. Early diagnosis is mandatory to address specific therapy and correct the timing of circulatory support. However, the diagnosis of myocarditis is challenging due to the heterogeneity of clinical presentations. Owing to its early onset, nonspecific symptomatology and fulminant progression, especially when these drugs are used in combination, oncologists should be vigilant for immune checkpoint inhibitor-related myocarditis. With many questions yet to be answered, from basic immune biology to clinical management, future research should aim to optimize the use of these drugs by identifying predictive biomarkers of either a response to therapy or the risks of myocarditis development.

Keywords: cytotoxic T-lymphocyte antigen 4; immune checkpoint inhibitors; immune-related adverse events; myocarditis; programmed cell death protein 1.

Publication types

  • Review

MeSH terms

  • Animals
  • Antigens / immunology
  • Autoimmunity
  • Humans
  • Models, Biological
  • Myocarditis / immunology*
  • Myocarditis / pathology
  • Myocardium / immunology
  • Myocardium / pathology
  • T-Lymphocytes / immunology

Substances

  • Antigens